Navigation Links
AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma
Date:12/16/2009

rifosine 50 mg daily or placebo. The Phase 3 trial design is based on positive data reported from the Phase 1/2 trial which was recently reported at the 51st American Society of Hematology meeting.

Patients eligible for the Phase 3 trial must have been previously treated with both bortezomib (Velcade(R)) and an immunomodulatory agent (Revlimid(R) and/or Thalidomid(R)), and been previously treated with one to four prior lines of therapy. The primary endpoint is progression-free survival and secondary endpoints include overall response rate, overall survival and safety. Patients can be relapsed from and refractory to all non-bortezomib based therapies, however, patients can only be relapsed (progressed more than 60 days after discontinuing therapy) from prior bortezomib-based therapies. The study is powered at 90% to demonstrate the required difference in progression-free survival between the two arms. Approximately 265 events (defined as disease progression or death) will trigger the un-blinding of the data.

The Company expects a patient recruitment period of approximately 16-18 months, with study completion expected within approximately 20-22 months from today.

About Perifosine (KRX-0401)

Perifosine is a novel oral anticancer agent that modulates several key signal transduction pathways, including Akt, MAPK, and JNK that have been shown to be critical for the survival of cancer cells. Perifosine has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. Perifosine is currently in a Phase 3 trial, under Special Protocol Assessment (SPA), in multiple myeloma for which it has received Orphan Drug and Fast Track designations from the FDA in this indication. Perifosine is also in Phase 2 clinical trials for several other tumor types.

About Multiple Myeloma

Multiple myeloma, a cancer of the plasma cell, is an incurable but t
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. AEterna Zentaris Announces Appointment of New Board Member
2. AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
3. AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia
4. AEterna Zentaris Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma
5. AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer
6. AEterna Zentaris Receives US$5.5 Million from Institutional Investors
7. AEterna Zentaris to Raise US$5.5 Million from Institutional Investors at US$1.20 Per Share
8. AEterna Zentaris to Complete Phase 3 Clinical Trial of Macimorelin (AEZS-130) as First Oral Diagnostic Test for Growth Hormone Deficiency
9. AEterna Zentaris Announces Completion of Phase 1 Study with Oral AEZS-112 in Cancer
10. AEterna Zentaris Partner, Keryx Biopharmaceuticals, Receives Orphan-Drug Designation for Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
11. AEterna Zentaris to Present at Upcoming Rodman Renshaw Annual Global Investment Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... --  Sequenom, Inc. (NASDAQ: SQNM ), ... solutions, and Mayo Medical Laboratories (MML), the ... the United States , have announced a license ... "We have great appreciation for Mayo Clinic,s commitment ... the opportunity to partner with the organization,s leading clinical ...
(Date:7/29/2014)... CITY, Md. , July 29, 2014 /PRNewswire/ ... announced a new and updated program for the ... 10 – 12, 2014 in Amelia Island ... CROs, sites and investigators remains unchanged, however, the ... purposeful exchange and networking opportunity among all stakeholders ...
(Date:7/29/2014)... SANTA CLARA, Calif. , July 29, 2014 ... research services agreement with FORMA Therapeutics, Inc., to ... capabilities and proprietary fragment-based lead discovery platform for ... are really excited about the opportunity to work ... the fields of epigenetics and protein homeostasis. FORMA ...
(Date:7/29/2014)... 29, 2014 July 29, 2014 ... in the biotechnology industry, announced that it has ... Inc. to explore financing opportunities that build shareholder ... breakthrough vaccine platform with the potential to transform ... exclusively licensed the well-established LAMP platform from Johns ...
Breaking Biology Technology:Sequenom Enters Into License Agreement With Mayo Medical Laboratories 2Sequenom Enters Into License Agreement With Mayo Medical Laboratories 3Sequenom Enters Into License Agreement With Mayo Medical Laboratories 4TransCelerate, Lilly, Pfizer, and FDA Highlight Collaborative Program at the Site Solutions Summit 2TransCelerate, Lilly, Pfizer, and FDA Highlight Collaborative Program at the Site Solutions Summit 3Nanosyn Announces Expanded Partnership With FORMA Therapeutics 2Immunomic Therapeutics Engages Newport Coast Securities, Inc. 2Immunomic Therapeutics Engages Newport Coast Securities, Inc. 3
... PRESENTS AT THOMAS WEISEL WEDNESDAY, SEPTEMBER 3RD AND NEWSMAKERS ... INDUSTRY CONFERENCE THURSDAY, SEPTEMBER 4TH, SAN DIEGO, Aug. ... today that Kevin Gorman, President and Chief,Executive Officer will ... Boston and the NewsMakers in the Biotech Industry Conference,in ...
... today announced it was named to Inc. magazine’s ... nationwide for a second consecutive year. The firm ... range of industries, helping companies operate more efficiently ... of the Chicago area’s top 100 businesses, growing ...
... ( www.chemlifecycle.com ) has finalized an agreement today with Chemical ... Management Systems (EMS) software for their new venture. , ... ... -- Chemical Lifecycle Management - a strategic alliance formed by ...
Cached Biology Technology:Neurocrine Biosciences to Present at Thomas Weisel Healthcare Conference and the NewsMakers in the Biotech Industry Conference 2 Integrated Project Management Named to "Inc. 5000" for Second Year : One of the Top 100 Fastest-Growing Companies in Chicago Area 2Chemical Lifecycle Management Chooses Chemical Safety's EMS Software 2
(Date:7/29/2014)... ground breaking new book that brings together two of ... raise the profile of insect fossils through stunning photographs ... Penney and James E Jepson, details the incredible preservation ... setting the scene for what these remarkable fossils can ... even the future of our planet. Like the mosquito ...
(Date:7/29/2014)... of cell, including sperm, bacteria and algae, propel ... protrusions, about one-hundredth of a millimetre long, function ... Similar, shorter structures called cilia are found on ... roles such as moving liquids over the cell. ... they transport mucus and expel pathogens from our ...
(Date:7/28/2014)... already approved by the U.S. Food and Drug Administration ... of certain bacterial pathogens inside human cells, including those ... The findings, published in mBio , the online ... a new way of identifying non-antibiotic drugs that could ... handful of drugs on the list inhibit the growth ...
Breaking Biology News(10 mins):Unique images bring fossil insects back to life 2Microscopic rowing -- without a cox 2Microscopic rowing -- without a cox 3New route to identify drugs that can fight bacterial infections 2
... WI, JUNE 30, 2011 -- Agroforestry, the deliberate placement ... capture substantial amounts of carbon on agricultural lands while ... tools for accurately estimating current and projected carbon values ... an effective carbon-capturing option. Only occupying about 2 to ...
... scientific results from an ambitious voyage led by a group ... San Diego offer a stark view of human pollution and ... been labeled as the "Great Pacific Garbage Patch." Two ... or SEAPLEX, found evidence of plastic waste in more than ...
... HFES invites you to register to attend the 55th ... Red Rock Hotel in Las Vegas! Early bird discounts ... the Registration Information page at http://www.hfes.org/web/HFESMeetings/2011registration.html for ... more. Online registration is available at http://tinyurl.com/3drb8hz . ...
Cached Biology News:Scripps study finds plastic in 9 percent of 'garbage patch' fishes 2Scripps study finds plastic in 9 percent of 'garbage patch' fishes 3HFES 2011 registration is now open 2
Chicken Anti-Human DNA-directed RNA Polymerase II 7.6 Kd Polypeptide (POLR2L Polyclonal AntibodyOther Sub-Family: not assigned-Other Applications: ELISA, Western Blot...
The BD CBA Human Apoptosis Kit can be used to quantitatively measure,cleaved PARP, Bcl-2, and active Caspase-3 protein levels in a single sample. The,Kit performance has been optimized for analysis o...
... ICE-family proteases/caspases initiates apoptosis in mammalian cells. ... Kit provides a simple and convenient means ... cytometry in intact cells. The assay ... residues linked to rhodamine 110 (D2R), a ...
The PROTEAN II slab gel casting stand is a component of the PROTEAN II XL and xi casting apparatus. It is supplied with gaskets....
Biology Products: